Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase
about
Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertensionTwo-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes.Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia.Intermittent hypoxia: cause of or therapy for systemic hypertension?Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertensionPyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension.Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles.Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon.Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate-salt hypertensionRole of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats.Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension.Role of proinflammatory cytokines and redox homeostasis in exercise-induced delayed progression of hypertension in spontaneously hypertensive rats.Profilin-1 promotes the development of hypertension-induced artery remodeling.Sesamin ameliorates arterial dysfunction in spontaneously hypertensive rats via downregulation of NADPH oxidase subunits and upregulation of eNOS expression.Treatment of endothelial cell with flavonoids modulates transendothelial leukocyte migration.Sodium nitrite exerts an antihypertensive effect and improves endothelial function through activation of eNOS in the SHR.Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat.Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension.Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model.Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells.Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats.Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats.Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet-fed mice.The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase-2 Up-Regulation in Renovascular Hypertension.Functional status of microvascular vasomotion is impaired in spontaneously hypertensive rat.Blood pressure normalization via pharmacotherapy improves cutaneous microvascular function through NO-dependent and NO-independent mechanisms.Possible involvement of orphan receptors GPR88 and GPR124 in the development of hypertension in spontaneously hypertensive rat.Intermittent hypoxia conditioning prevents endothelial dysfunction and improves nitric oxide storage in spontaneously hypertensive rats.
P2860
Q28567348-CDCC1381-7FB7-4648-9BDD-4A6B38C1BA8FQ33283202-93C958F8-370E-43EF-A1BD-128154A017D7Q34022778-8282F36C-14FD-4585-BD0A-3632788DE176Q34154805-B0265DAC-94C3-47C3-BF06-DDFBED68D733Q34769610-874592EB-D8D5-43B6-B232-9918D728AA42Q35110074-4BA490FF-14C2-4EDF-81B6-21C62534EF73Q35216484-26E8DC49-54F7-4373-A481-D6A7A93931F6Q35546284-0FE79F2A-7A0B-4F25-9283-05F0FC5380CFQ35638918-6ABA6604-1C0C-4150-9E9D-6CBBFE3DB879Q35952223-3BFEA998-4FD5-4F97-BA31-AEACE36B3067Q36148204-71100A1C-8954-4B7D-8C7F-2D25DCACDBAAQ36495144-91A01F10-D85B-4A2C-BC4B-F2134885283FQ37085195-00E821A5-4E22-4282-BA35-2E7FE0D4B3E9Q37427409-A0EDB078-9926-4B47-B2D4-0DA94A08A209Q37664269-BF84EF31-0849-44DD-81D2-9EE678546ED9Q37728516-BBB9B7B7-6728-44D8-A3CB-9CF4132976C6Q38998963-6E32CE7F-8D54-4344-9E9B-AD451B2575BEQ41063658-65B78E5F-9C0A-4509-9CD5-2B2059A16968Q41821185-E1BBC9E5-80A8-4F56-BC30-35808EEB78E2Q42229127-83208EDF-2784-4C19-A309-ED363117CDFCQ43111529-2AD08AE4-5170-4DA7-BD6A-C4462E8FEB8DQ43852568-8D42DA7D-3FC2-49C6-88C8-FE6AC6D4AE42Q45219982-8127CDE3-D25A-4E3F-A9B3-47C6C590EE5BQ46385767-AFE6ECE9-7344-46FA-9CB0-8DD7A6D80A55Q46509676-5949484E-A42D-4CAA-B5B5-B92FD91EFA66Q46752526-CA47481E-8147-4296-9CD4-DCEC86DE8890Q47131073-B22AAF71-9D75-4C1E-9910-BA5972C6F89EQ48135874-F902021D-0F4E-49D8-AADF-6EA7D4BF1E10Q48210992-C365D26F-2096-4CF6-86BD-EB640074D969Q51864825-335E2365-23C4-430A-8300-F9179DD1F4F8
P2860
Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Suppression of the development ...... nducible nitric oxide synthase
@en
type
label
Suppression of the development ...... nducible nitric oxide synthase
@en
prefLabel
Suppression of the development ...... nducible nitric oxide synthase
@en
P2093
P2860
P356
P1476
Suppression of the development ...... nducible nitric oxide synthase
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0703603
P407
P577
2000-10-01T00:00:00Z